Reviewer declaration of interest A reviewer on this manuscript has disclosed that they are an investigator on the oral semaglutide clinical trials. Author Contribution Statement All authors participated in the conception and trial design. AB was involved in the trial conduct and acquisition of data. All authors were involved in data analysis and interpretation, and participated in drafting of the manuscript or revising it critically for intellectual content. All authors have approved the submitted manuscript and agree to be accountable to all aspects of the work. References Papers of special note have been highlighted as either of interest ()o ro f considerable interest () to readers. 1. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide- 1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696– 1705. 2. Verspohl EJ. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther.2009;124:113– 138. 3. Marso SP, Bain SC, Consoli A, et al. SUSTAIN-6 Investigators. 